Clinic Roundup

GenSpera Inc., of San Antonio, said UK regulators cleared the firm for a Phase II trial of G-202 in prostate cancer patients who have failed prior hormonal therapy. The study is expected to enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant disease.